Paroxetine

Introduction Overview

Generic Name

paroxetine

Brand Name

Paxil

Dosage Form

oral tablets, extended-release tablets, oral suspension

Drug Class

Selective serotonin reuptake inhibitors (SSRIs)

Pharmacokinetics

Absorption:
Paroxetine is well absorbed following oral administration, with peak plasma concentrations typically observed within 5 to 6 hours after ingestion of immediate-release formulations. Food does not significantly affect the rate or extent of absorption, which facilitates flexible dosing with or without meals. The bioavailability of paroxetine is somewhat variable due to extensive first-pass metabolism, but generally averages around 50-70%. Extended-release formulations (Paxil CR) provide a slower, more controlled absorption, with peak concentrations occurring approximately 10 to 12 hours post-dose, resulting in steadier plasma levels and reduced peak-trough fluctuations.

Distribution:
Paroxetine is widely distributed throughout body tissues with a volume of distribution approximately 20-40 L/kg, indicating extensive tissue uptake. It is highly bound to plasma proteins, specifically albumin and alpha-1-acid glycoprotein, with a binding rate of approximately 95%. The drug crosses the blood-brain barrier effectively, concentrating in the central nervous system (CNS) where it exerts its pharmacologic effects. Paroxetine also crosses the placenta and is detectable in breast milk, leading to clinical considerations during pregnancy and lactation.

Metabolism:
Paroxetine undergoes extensive hepatic metabolism primarily via the cytochrome P450 enzyme CYP2D6. It is both a substrate and a potent inhibitor of CYP2D6, leading to potential drug interactions. The biotransformation process results in multiple metabolites, none of which display significant pharmacological activity. Due to genetic polymorphism in CYP2D6 among individuals, metabolism rates can vary, potentially affecting plasma concentrations. Chronic use can inhibit its own metabolism by saturating CYP2D6, which may alter steady-state concentrations.

Elimination:
Paroxetine elimination occurs mainly via hepatic metabolism with less than 2% excreted unchanged in urine. The elimination half-life ranges from 21 to 24 hours, supporting once-daily dosing regimens. Steady-state plasma concentrations are achieved within 7 to 14 days of daily dosing. Excretion of metabolites is primarily renal. Impaired hepatic function can prolong elimination, necessitating dosage adjustments. Additionally, elderly patients may exhibit reduced clearance, increasing exposure and risk for adverse effects.

Dosage Forms

Available Dosage Forms:
- Immediate-release oral tablets: 10 mg, 20 mg, 30 mg, and 40 mg
- Extended-release (CR) oral tablets: 12.5 mg, 25 mg, and 37.5 mg
- Oral suspension (liquid formulation): 10 mg/5 mL

Dosages for Adults and Adolescents:
- Major depressive disorder, generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, PTSD, and premenstrual dysphoric disorder: Initial dose usually 20 mg once daily, with titration based on clinical response and tolerability, up to a maximum of 50 mg daily for most indications.
- For panic disorder and OCD, starting doses may begin at 10 mg once daily.
- Dose adjustments should be individualized, considering patient response and side effect profile.
- Extended-release tablets can improve gastrointestinal tolerability and provide smoother plasma concentration profiles.

Specific Patient Populations:
- Elderly: Initiate at lower doses (e.g., 10 mg daily) with cautious titration due to higher sensitivity and risk of side effects.
- Hepatic impairment: Dose reduction recommended as metabolism may be significantly slowed.
- Renal impairment: Generally no dose adjustment necessary, but monitor for side effects.
- Pediatric Use: Not approved for patients under 18 years except under careful medical supervision in select populations.
- Pregnancy: Use only if benefits outweigh risks due to potential neonatal complications.

Clinical Guidelines:
- Paxil should be administered once daily generally in the morning or evening, with the extended-release formulation swallowed whole without crushing or chewing.
- Oral suspension should be shaken well before dosing and dosed using a proper measuring device or syringe.
- Abrupt discontinuation should be avoided to minimize withdrawal symptoms; tapering is recommended under medical supervision.

Mechanism Of Action

Paroxetine exerts its primary pharmacological effect through selective inhibition of the serotonin transporter (SERT) located on presynaptic neuronal membranes. By binding to SERT, paroxetine blocks the reuptake of serotonin (5-hydroxytryptamine, 5-HT) into presynaptic neurons, thereby increasing the availability of serotonin in the synaptic cleft. This elevated serotonergic neurotransmission enhances postsynaptic receptor activation, which is believed to contribute to its antidepressant and anxiolytic effects.

At the cellular level, paroxetine's action results in downstream modulation of neuronal signaling and plasticity. Chronic administration leads to alterations in receptor sensitivity, gene expression, and neurotrophic factors such as brain-derived neurotrophic factor (BDNF), which are thought to underpin the long-term therapeutic benefits in depression and anxiety disorders. Paroxetine does not have significant affinity for adrenergic, histaminergic, or muscarinic receptors, which contributes to its favorable side effect profile compared to older antidepressants.

Clinically, paroxetine’s ability to selectively increase synaptic serotonin without markedly affecting norepinephrine or dopamine distinguishes it from other antidepressant classes, such as SNRIs or tricyclic antidepressants. Research evidence supports paroxetine’s efficacy in multiple psychiatric conditions including major depressive disorder, generalized anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, and premenstrual dysphoric disorder.

Comparatively, paroxetine exhibits a potent inhibition profile of SERT and also demonstrates mild anticholinergic properties, which may contribute to some adverse effects such as dry mouth and sexual dysfunction. Its strong CYP2D6 inhibitory effect causes significant potential drug-drug interactions. Clinical trials have shown that paroxetine’s efficacy is comparable to other SSRIs, with some evidence suggesting that it may be particularly effective in anxiety spectrum disorders.

Pharmacological Actions

Selective inhibition of serotonin reuptake transporter (SERT) leading to increased synaptic serotonin levels.
Enhancement of serotonergic neurotransmission resulting in antidepressant and anxiolytic effects.
Modulation of neuronal plasticity and neurotrophic factor expression (e.g., BDNF) with chronic use.
Weak anticholinergic activity contributing to some side effects.
Inhibition of hepatic CYP2D6 enzyme, affecting metabolism of various other drugs.
Minimal affinity for adrenergic, histaminergic, and dopaminergic receptors, limiting off-target effects.
Reduction of anxiety symptoms by modulating serotonergic circuits in limbic brain regions.
Potential delay in ejaculation via enhanced serotonergic activity, aiding in treatment of premature ejaculation.
Stabilization of mood and reduction of panic attacks by altering brain serotonin levels.
Improvement in obsessive-compulsive behaviors via enhanced serotonin signaling.
Diminution of PTSD symptoms through serotonergic modulation.
Regulation of premenstrual dysphoric disorder symptoms via central serotonin pathways.

Therapeutic Or Clinical Uses

Treatment of major depressive disorder (MDD) in adults.
Management of panic disorder with or without agoraphobia.
Treatment of obsessive-compulsive disorder (OCD) in adults.
Management of generalized anxiety disorder (GAD).
Treatment of social anxiety disorder (social phobia).
Management of post-traumatic stress disorder (PTSD).
Treatment of premenstrual dysphoric disorder (PMDD).
Off-label use for premature ejaculation due to serotonergic delay of ejaculation.
Adjunct in certain anxiety-related mental health conditions where SSRIs are indicated.
Used as part of psychopharmacologic therapy in mood and anxiety spectrum disorders.
May be considered in refractory cases of depressive or anxiety disorders after clinical evaluation.
Research investigating its utility in other serotonergic dysfunction disorders.
Symptomatic relief in complex dysautonomia as adjunct therapy.

Side Or Adverse Effects

Common side effects include nausea, vomiting, diarrhea, and constipation reflecting gastrointestinal irritation.
Central nervous system effects such as dizziness, drowsiness, fatigue, and headache.
Insomnia or other sleep disturbances including abnormal dreams.
Sexual dysfunction (decreased libido, delayed ejaculation, impotence, anorgasmia).
Dry mouth and excessive yawning.
Increased sweating (hyperhidrosis).
Weight changes including weight gain or loss depending on duration and patient.
Risk of serotonin syndrome, especially when combined with other serotonergic agents.
Possible induction of manic or hypomanic episodes in bipolar patients.
Potential for withdrawal syndrome characterized by dizziness, sensory disturbances, anxiety, irritability if stopped abruptly.
Hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH), especially in elderly.
Rare but serious allergic reactions including angioedema and rash.
Increased risk of bleeding or bruising, especially if taken with NSAIDs or anticoagulants.
Potential for suicidal ideation particularly in children, adolescents, and young adults during initial therapy.
Visual disturbances including blurred vision or tunnel vision in rare cases.

Precautions

Use caution in patients with a history of bipolar disorder due to risk of inducing mania.
Monitor closely for suicidal ideation or behaviors early during treatment and during dose changes.
Careful titration and monitoring advised in elderly patients due to increased risk of hyponatremia and falls.
Avoid abrupt discontinuation to minimize withdrawal symptoms; taper dose gradually.
Exercise caution in patients with hepatic impairment; dose adjustment may be necessary.
Be aware of the increased bleeding risk, especially in patients concurrently taking NSAIDs, anticoagulants, or with bleeding disorders.
Patients with seizure disorders require careful monitoring as paroxetine may lower seizure threshold.
Evaluate for serotonin syndrome when used concomitantly with other serotonergic drugs.
Not recommended during pregnancy unless potential benefit justifies the potential risk to the fetus.
Avoid breastfeeding due to excretion in human milk and potential adverse effects in nursing infants.
Monitor serum sodium levels in patients at risk for hyponatremia.
Advise patients about possible sexual side effects and offer management strategies.
Use caution in patients with narrow-angle glaucoma due to potential anticholinergic effects.
Careful assessment required when co-administered with drugs influencing cytochrome P450 enzymes.
Avoid operating heavy machinery or driving until drug effects are known due to possible dizziness or drowsiness.

Warnings

Do not use Paxil concomitantly with pimozide or thioridazine due to risk of serious cardiac arrhythmias.
Avoid use within 14 days before or after treatment with monoamine oxidase inhibitors (MAOIs) to prevent serotonin syndrome.
Monitor for signs of serotonin syndrome including agitation, hallucinations, muscle rigidity, fever, sweating, and tachycardia.
Risk of increased suicidal thoughts and behaviors in children, adolescents, and young adults during initial treatment.
Sudden discontinuation can cause withdrawal symptoms such as dizziness, sensory disturbances, and mood swings.
Potential for serious allergic reactions including anaphylaxis and severe skin reactions.
Use caution in patients with a history of bleeding disorders as paroxetine may increase bleeding risk.
May cause hyponatremia, especially in elderly or patients taking diuretics.
Avoid alcohol consumption while taking Paxil as it can enhance CNS depressive effects.
Not approved for pediatric use under 18 years except in certain conditions.
Pregnancy use carries risk for neonatal complications including persistent pulmonary hypertension of the newborn.
Advise careful monitoring of blood pressure as paroxetine can interact with antihypertensive agents.
Risk of drug interactions due to potent inhibition of CYP2D6 enzyme.
Do not crush or chew extended-release tablets to avoid rapid release and increased adverse effects.
Warn patients regarding impaired ability to perform hazardous tasks such as driving until effects are known.

Contraindication

Known hypersensitivity to paroxetine or any component of the formulation.
Concomitant use with pimozide or thioridazine due to risk of cardiac arrhythmias.
Use with monoamine oxidase inhibitors (MAOIs) within 14 days before or after paroxetine administration.
History of serotonin syndrome or hypersensitivity reactions to SSRIs.
Concurrent use with linezolid or intravenous methylene blue due to risk of serotonin toxicity.
Patients with untreated narrow-angle glaucoma due to potential increase in intraocular pressure.
Patients with severe hepatic impairment have restricted use; contraindications based on physician discretion.
Known hypersensitivity or adverse reactions to other SSRIs suggesting cross-reactivity.
Contraindicated in pediatric patients under 18 years except with specific psychiatric indications.
Avoid in patients with concomitant use of other serotonergic drugs without strict monitoring.

Drug Interactions

MAO inhibitors (e.g., isocarboxazid, phenelzine, selegiline) – serious risk of serotonin syndrome; contraindicated within 14 days.
Other serotonergic agents including triptans, tramadol, lithium, buspirone – increased risk of serotonin syndrome.
CYP2D6 substrate drugs (e.g., tamoxifen, codeine) – paroxetine inhibits CYP2D6, reducing their efficacy.
Warfarin and other anticoagulants – increased risk of bleeding and bruising.
NSAIDs and antiplatelet agents – further elevated bleeding risk when combined with paroxetine.
Stimulants used for narcolepsy or ADHD (amphetamine, atomoxetine) – potential additive CNS effects.
Opioids such as fentanyl, tramadol – increased CNS depression and risk of serotonin syndrome.
Cimetidine – may increase plasma concentrations of paroxetine by inhibiting metabolism.
Digoxin – possible interaction necessitates monitoring of digoxin levels.
Tamoxifen – paroxetine may reduce its activation leading to decreased clinical effectiveness.
Phenytoin and phenobarbital – may reduce paroxetine plasma concentrations via enzyme induction.
Linezolid and intravenous methylene blue – risk of hypertensive crisis and serotonin syndrome.
Herbal supplements like St. John's wort – increased serotonergic activity and risk of serotonin syndrome.
Diuretics – increased risk of hyponatremia when combined with paroxetine.
Drugs causing CNS depression (benzodiazepines, alcohol) – additive sedative effects.

Preparations Of The Drug

Paroxetine immediate-release tablets (10 mg, 20 mg, 30 mg, 40 mg).
Paroxetine controlled-release (CR) tablets (12.5 mg, 25 mg, 37.5 mg) offering once-daily dosing with improved tolerability.
Paroxetine oral suspension (liquid) concentration 10 mg/5 mL for patients unable to swallow tablets.
Brand formulations include Paxil, Paxil CR, Pexeva, and Brisdelle (a formulation specifically indicated for menopausal hot flashes).
Available in generic form with equivalent bioavailability to branded products.
Tablets are non-scored and should not be crushed or chewed, especially CR forms.
Packaging varies from blister packs to bottles with child-resistant caps depending on manufacturer.
Some preparations include patient information leaflets with detailed dosing and safety instructions.
Oral suspension requires shaking before administration and use of calibrated measuring devices.
Extended-release forms are intended for gradual release and steady plasma concentrations.
Multiple dosage strengths facilitate individualized dosing adjustments based on response and tolerability.